



PRESS RELEASE

Publicerat: 2017-09-26

Inhalation Sciences strengthens its sales organisation

STOCKHOLM, SWEDEN – 26 September, 2017. With the announcement of Ola Nerbrink (PhD) as senior Sales Advisor, Inhalation Sciences (ISAB) is significantly strengthening its PreciseInhale commercialization team.

Ola Nerbrink is an internationally experienced inhalation expert and previous CEO of Medicon Valley Inhalation Consortium (MVIC), one of Europe's largest business clusters around inhalation research. Ola has experience working with Astra Zeneca and Novo Nordisk, amongst others, and has published over 20 peer-reviewed articles in the field of inhalation.

"Ola's international network in research and pharma is invaluable," says ISAB Fredrik Sjövall. "He understands how to best connect medical and financial decision makers. We've received enormous interest in PreciseInhale amongst active researchers. We believe we can shorten sales time by more effectively supporting them in their relationship with economic decision makers."

"I'm looking forward to working with Fredrik Sjövall, Per Gerde and the ISAB team," says Ola Nerbrink. "PreciseInhale is a unique system that fundamentally improves inhalation research, in the coming years it could make a big difference for both pharma companies and research institutes."

ISAB recently carried out an oversubscribed share issue ahead of its listing on *Aktietorget*, where the first day of trading is scheduled for September 28.

Brief facts about ISAB

Inhalation Sciences Sweden AB develops and sells advanced lab equipment for inhalation R&D that measures how particles in inhaled air affect our health. ISAB has a number of licensed patents in the EU, US, Japan and China, a proven product and business model with revenue from pilot customers and Key Opinion Leaders totalling approximately 25 MSEK over the last three years. The company is now facing a phase of increased sales and faster growth in a growing market with high potential.

For more information about Inhalation Sciences please contact:

Fredrik Sjövall, CEO
Email: fredrik.sjovall@inhalation.se
Phone: +46 (0)70 64 508 75

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company's patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when we breathe them in.